

## Corporate Fact Sheet

|                              |  |
|------------------------------|--|
| <b>Overview</b>              | <p>Alucent Biomedical is a privately held biomedical company dedicated to developing and commercializing its breakthrough Natural Vascular Scaffolding (Alucent NVS) Vessel Restoration System with Photoactivated Linking for the treatment of peripheral artery disease (PAD) of the lower extremities. The company recently announced that it will also seek to adapt the technology for the maturation and preservation of arteriovenous fistula (AVF) for hemodialysis (HD).</p> <p>Alucent Biomedical was founded by the Avera Research Institute, part of the multistate Avera Health System, with the first employee hired in 2017.</p>  |
| <b>Market Focus</b>          | <p><b>Peripheral Artery Disease:</b> PAD, our main focus, is a debilitating, painful and highly prevalent condition in which arteries of the lower extremities become narrowed due to a build-up of atherosclerotic plaque. PAD impacts eight to 10 million people in the U.S. and more than 200 million people worldwide.<sup>1</sup> The global market for related peripheral vascular devices, including stents and balloons, is \$3.2 billion, of which \$2.5 billion is the U.S. market.<sup>2</sup></p> <p><b>Arteriovenous Fistula:</b> The prevalence of end-stage renal disease continues to rise, and there is a growing need for hemodialysis. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines and the Fistula First Breakthrough Initiative recommend AVFs as the preferred type of vascular access for HD, as they have superior patency rates, fewer complications and lower health care costs.</p> |
| <b>Product</b>               | <p>Alucent is devoted to developing and commercializing the Alucent NVS Vessel Restoration System with Photoactivated Linking, a therapy that has the potential to significantly improve patients' lives. The system creates a Natural Vascular Scaffold (Alucent NVS) through photoactivated linking of native structural proteins in the vessel wall. It is designed to keep vessels open following intravascular procedures without the use of permanent implants.</p>  |
| <b>Intellectual Property</b> | <p>Alucent has exclusively licensed nine issued U.S. and international patents from Alumend LLC. The patents cover all vascular uses. Alucent has filed nine additional new patent applications in 2018 through 2020 covering specific product embodiments.</p>  |
| <b>Financing</b>             | <p>Alucent has been supported with more than \$24 million of capital from Avera Health since 2017 before raising \$35 million in a Series B funding in 2020. This funding is expected to finance the company's activities through the end of 2022. With this recent funding, Alucent has a primary goal of achieving robust proof of safety and efficacy of a fully integrated, commercially ready product.</p>  |

<sup>1</sup> Caradu, Caroline et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. *Journal of Vascular Surgery*. Volume 70, Issue 3, 981-995.e10.

<sup>2</sup> Decision Research Group Market Research Reports. *Peripheral Vascular Devices (US, EU)*. 2019. Numbers shown for 2020

**Management Team**

- Myles Greenberg, M.D., President, Chief Executive Officer
- Hank Hauser, Vice President, Clinical Affairs
- Katalin Kauser, M.D., PhD, DSc, Vice President, Biology
- Bruce Krattenmaker, Vice President, Regulatory Affairs
- Scott Mayfield, Vice President, Finance & Administration
- Krishna Rocha-Singh, M.D., FACC, Acting Medical Director
- Steve Tyler, Vice President, R&D/Engineering
- Kevin Warner, PhD, Vice President, Pharmaceutical Development
- Jim Isaacson, Senior Director of Quality and Regulatory Affairs

**Scientific and Clinical Advisory Board**

- Gary Ansel, M.D., FACC, OhioHealth
- Elazer R. Edelman, M.D., PhD, FACC, Massachusetts Institute of Technology
- William Gray, M.D., FACC, Main Line Health
- Larry W. Kraiss, M.D., FACS, University of Utah
- William C. Sessa, PhD, Yale University School of Medicine
- Ron Utecht, Ph.D. Founder
- Craig Walker, M.D., FACC, Cardiovascular Institute of the South
- Venita Chandra, MD, FACS, Stanford Medicine

**Corporate Headquarters:**

Alucent Biomedical Inc.  
675 Arapeen Drive, Suite 102  
Salt Lake City, UT 84108  
Phone: (385) 722-2300

**MEDIA CONTACT:**

Diana Soltesz  
Senior Associate  
Pazanga Health Communications  
818-618-5634  
dsoltesz@pazangahealth.com